Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Globus Medical Inc

NYSE: GMED · Industrial Applications and Services · 5 alerts · CIK 1237831

Share price
$70.50Close, Nov 16
Market cap
$9.47B
Shares outstanding
134.26MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Globus Medical Inc filings on SEC EDGAR ↗

6:12 PM ET Form 4
Insider Selling

Globus Medical Director James R. Tobin Sells $3.13M of Stock

James R. Tobin, Director, sold 41,666 shares of Globus Medical Inc at $75.10 to $75.68 a share (average $75.16) in 2 transactions, worth $3.13M in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).

Value
$3.13M
Shares
41,666
Average price
$75.16
Role
Director
Holding change
-100.0%
Trade date
Nov 10, 2026
5:34 PM ET Form 4
Insider Selling

Globus Medical Director Ann D. Rhoads Sells $425K of Stock

Ann D. Rhoads, Director, sold 5,000 shares of Globus Medical Inc at $85.00 a share, worth $425K in total on Nov 4, 2026. Shares held after the trade: 35,384 (-12.4%).

Value
$425K
Shares
5,000
Price
$85.00
Role
Director
Holding change
-12.4%
Trade date
Nov 4, 2026
5:08 PM ET 10-Q
Financial Results

Globus Medical Q3 2026 Results: Net Income $141M, Up 18.7% YoY

Globus Medical reported net sales of $2.31 billion for the nine months ended September 30, 2026, a 9.5% increase over the prior year. Net income for the same period rose to $417.0 million, driven by higher operating income and a bargain purchase gain, while the company maintained a strong balance sheet with $4.8 billion in total equity.

Key figure
Net income $141M · +18.7% YoY
4:14 PM ET 8-K
Financial Results

Globus Medical Financial Results

Globus Medical reported Q3 2026 financial results with net sales of $763.7 million and GAAP net income of $141.2 million. Simultaneously, the company announced that its Board of Directors authorized a $500 million increase to its existing share repurchase program, bringing the total available for future buybacks to approximately $611 million.

“Third quarter revenue finished at $764 million, down slightly from the prior year quarter. U.S. Spine faced difficult prior year comparables, growing 2% in the third quarter, as compared to double digit growth in the prior year quarter. On an average two-year basis, the U.S. Spine business is growing mid-single digits, reflecting our ability to capture share in the market, as we lead with innovation and differentiation.”

Keith Pfeil, President and Chief Executive Officer

“Our third quarter results highlight our Company’s commitment to delivering consistent adjusted gross profit margin expansion, bottom-line profit, and free cash flow generation, as we delivered the eighth straight quarter of sequential adjusted gross profit margin expansion and record quarterly operating cash flow and free cash flow generation.”

Kyle Kline, Chief Financial Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.